Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tick-borne encephalitis virus (inactivated) neudoerfl - suspension for injection in pre-filled syringe - 0.25 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Israel - English - Ministry of Health

kamada ltd, israel - japanese encephalitis purified inactivated vaccine - suspension for injection - japanese encephalitis purified inactivated vaccine 6 au / 0.5 ml - encephalitis, japanese, inactivated, whole virus - ixiaro is indicated for active immunization against japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) - injection, suspension - 6 μg/0.5 ml - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) 6 μg/0.5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - japanese encephalitis virus, quantity: 4 pfu - injection, powder for - excipient ingredients: albumin; mannitol; glutamic acid; histidine; sodium chloride; potassium hydroxide; lactose monohydrate; water for injections - imojev is indicated for prophylaxis of japanese encephalitis caused by the japanese encephalitis virus, in individuals from 9 months of age and over.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - suspension for injection - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus - ticovac 0.5 ml is indicated for the active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (tbe).

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - suspension for injection - encephalitis, tick borne, inactivated, whole virus 1.2 mcg / 0.25 ml - encephalitis, tick borne, inactivated, whole virus - ticovac junior 0.25 ml is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).

Israel - English - Ministry of Health

kamada ltd, israel - cytomegalovirus antibody; human plasma protein; immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 96 %; human plasma protein 50 mg/ml; cytomegalovirus antibody 100 u/ml - cytomegalovirus immunoglobulin - prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients.the concomitant use of adequate virostatic agents should be considered for cmv-prophylaxis.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - japanese encephalitis vaccine 6 units - suspension for injection - 6 u/dose - active: japanese encephalitis vaccine 6 units excipient: aluminium hydroxide gel dibasic sodium phosphate monobasic potassium phosphate sodium chloride - jespect® is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect® should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect® is indicated for persons who work with je virus in laboratories and in industry.